“Progressive Supranuclear Palsy Epidemiology” report has been recently added to DelveInsight
About Progressive Supranuclear Palsy
Progressive Supranuclear Palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech and swallowing. The condition has been linked to changes in certain genes, but these genetic faults are not inherited and the risk to other family members (including the children or siblings) with PSP, is very low.
Get free sample copy of Progressive Supranuclear Palsy epidemiology report- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-epidemiology-forecast
Progressive Supranuclear Palsy Epidemiology
Progressive Supranuclear Palsy (PSP) also called Steele-Richardson-Olszewski syndrome, is an uncommon brain disorder that affects movement, control of walking (gait) and balance, speech, swallowing, vision, mood and behavior, and thinking. The cause of PSP is not known, but it is a form of tauopathy, in which abnormal phosphorylation of the protein tau leads to destruction of vital protein filaments in nerve cells, causing their death.
Important facts of Progressive Supranuclear Palsy Epidemiology report
- “Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data”, crude prevalence of PSP was 1.89 per 100,000 and age-standardized prevalence to the US population was 2.95 per 100,000. A little over half (53.5%) of patients were male.
- Estimated that the prevalence of PSP in the UK was 1.0 per 100,000. The age-adjusted standardized prevalence figure for PSP from this study mwas observed to be 5.0.
- According to a study conducted by Kawashima et al. 2004, in Japan the prevalence of PSP was 5.82 per 100,000 (men, 9.14; women, 2.75).
Progressive Supranuclear Palsy Diagnosis
There’s no single test for PSP. Instead, the diagnosis is based on the pattern of the symptoms. The large number of possible symptoms of PSP also makes it difficult to diagnose correctly and can mean it takes a while to get a definitive diagnosis. Apart from this, PSP is often misdiagnosed as Parkinson disease, Alzheimer disease, corticobasal degeneration and other neurodegenerative disorders.
Progressive Supranuclear Palsy Epidemiology Segmentation
- Total Prevalent cases of Progressive Supranuclear Palsy (PSP) in 7MM [2017–2030]
- Type-Specific Prevalent Cases of PSP in the 7MM [2017–2030]
- Gender-Specific Prevalent Cases of PSP in 7MM [2017–2030]
- Diagnosed and Treatable Cases of PSP in the 7MM [2017–2030]
- Age-Specific Prevalent Cases of PSP in 7MM [2017–2030]
Progressive Supranuclear Palsy Treatment
Treatment of PSP is symptomatic and supportive. There is no cure of the disease at the present time. Drugs prescribed to treat Parkinson’s disease, such as ropinirole, rarely provide additional benefit. In some individuals the slowness, stiffness, and balance problems of PSP may respond to some degree to antiparkinsonian agents such as levodopa, but the effect is usually minimal and short-lasting. Excessive eye closing can be treated with botulinum injections. Some antidepressant drugs may provide benefit beyond treating depression, such as pain relief and decreasing drooling.
Progressive Supranuclear Palsy Epidemiology: Report Scope
- The Progressive Supranuclear Palsy report covers a detailed overview explaining its etiology, pathophysiology classification, diagnosis, and treatment patterns.
- The Progressive Supranuclear Palsy report and model provide an overview of the global trends of Progressive Supranuclear Palsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides insight into the historical and forecasted patient pool of Progressive Supranuclear Palsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- The report helps recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of Progressive Supranuclear Palsy.
- The report provides the segmentation of the Progressive Supranuclear Palsy epidemiology
Get free sample copy of Progressive Supranuclear Palsy epidemiology report- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-epidemiology-forecast
Following is the table of content of Progressive Supranuclear Palsy epidemiology report
1 Key Insights
2 Executive Summary of Progressive Supranuclear Palsy
3 SWOT Analysis for Progressive Supranuclear Palsy
4 Progressive Supranuclear Palsy (PSP) Epidemiology Overview at a Glance
5 Disease Background and Overview: Progressive Supranuclear Palsy (PSP)
6 Epidemiology and Patient Population
7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)
8 Treatment
9 Unmet Needs
10 Appendix
11 DelveInsight Capabilities
12 Disclaimer
13 About DelveInsight
What are the reasons to buy this report?
- Develop business strategies by understanding the trends shaping and driving the global Progressive Supranuclear Palsy market.
- Quantify patient populations in the global Progressive Supranuclear Palsy market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Progressive Supranuclear Palsy therapeutics in each of the markets covered
- Understand the magnitude of Progressive Supranuclear Palsy population by its epidemiology
- The Progressive Supranuclear Palsy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Related Reports
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/